Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Quest Diagnostics (NY: DGX ) 155.29 +0.46 (+0.30%) Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Quest Diagnostics < Previous 1 2 3 4 5 6 7 8 9 10 Next > Employers Struggle with Drug Test Policies Amid Varying State Laws, Cheating on Drug Tests Reaches 30-Year High May 15, 2024 Cheating on drug tests among American workers has reached a 30-year high, with Quest Diagnostics Inc. reporting 31,000 tampered samples out of 5.5 million in 2023. The rise in synthetic urine use and... Via Benzinga Topics Cannabis Exposures Cannabis Intelligent Bio Solutions Screening Technologies Poised to Disrupt The Healthcare Sector: INBS, LH, ABT, DGX April 30, 2024 Via AB Newswire Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week April 29, 2024 With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. Via Benzinga Topics Stocks Exposures US Equities Intelligent Bio Solutions’ Fingerprint Drug Screening Technology Poised For Massive Growth April 25, 2024 Intelligent Bio Solutions (Nasdaq: INBS) is a medical technology company developing and commercializing innovative, intelligent, rapid, noninvasive testing solutions. Via Talk Markets Peering Into Quest Diagnostics's Recent Short Interest April 24, 2024 Via Benzinga The Analyst Landscape: 5 Takes On Quest Diagnostics April 24, 2024 Via Benzinga Balancing Dividends and Fundamentals: The Case of NYSE:DGX. April 10, 2024 Uncovering Dividend Opportunities with QUEST DIAGNOSTICS INC (NYSE:DGX). Via Chartmill Key Takeaways From Quest Diagnostics Analyst Ratings March 20, 2024 Via Benzinga Why NYSE:DGX provides a good dividend, while having solid fundamentals. March 19, 2024 Balancing Dividends and Fundamentals: The Case of QUEST DIAGNOSTICS INC (NYSE:DGX). Via Chartmill Quest Diagnostics Says Sales In Q1 Increased For The First Time Since The Height Of Pandemic April 23, 2024 Latest financial insights from Quest Diagnostics. Q1 results beat estimates with adjusted EPS of $2.04 and sales of $2.34 billion, showcasing nearly 6% base business revenue growth. Via Benzinga DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q1 2024 April 23, 2024 DGX stock results show that Quest Diagnostics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace US Stocks Set To Open Fresh Week Higher On Big Tech Earnings Hopes: Analyst Warns Any Letdown Could Push Market 'Deeper Into Oversold Territory' April 22, 2024 Wall Street appears to be shrugging off rate worries as major stock index futures were moderately higher in early pre-market trading on Monday in the hopes of getting some respite from Big Tech... Via Benzinga LifeMD Shares Come Back to Life on GLP-1 Business Growth March 19, 2024 LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024 Via MarketBeat (DGX) - Analyzing Quest Diagnostics's Short Interest March 05, 2024 Via Benzinga Why NYSE:DGX provides a good dividend, while having solid fundamentals. February 27, 2024 Balancing Dividends and Fundamentals: The Case of QUEST DIAGNOSTICS INC (NYSE:DGX). Via Chartmill Earnings Scheduled For April 23, 2024 April 23, 2024 Companies Reporting Before The Bell • RTX (NYSE:RTX) is expected to report quarterly earnings at $1.23 per share on revenue of $18.41 billion. Via Benzinga Breaking Down Quest Diagnostics: 7 Analysts Share Their Views February 26, 2024 Via Benzinga Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week April 21, 2024 Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. Via Benzinga AMC Entertainment Tops The List Of High-Yielding Corporate Bonds — A Look At Yields As Bond Appetites Grow March 18, 2024 Benzinga used Public.com's bond screener tool to identify some of the highest-yielding investment-grade corporate bonds. Via Benzinga Topics Bonds Exposures Debt Markets Spotify To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Wednesday February 07, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Is NYSE:DGX suited for dividend investing? February 05, 2024 Analyzing QUEST DIAGNOSTICS INC (NYSE:DGX)'s Dividend Potential. Via Chartmill Beyond The Numbers: 7 Analysts Discuss Quest Diagnostics Stock February 02, 2024 Via Benzinga Investor Sentiment Falls Sharply Following Fed's Rate Decision; Dow Dips Over 300 Points February 01, 2024 The CNN Money Fear and Greed index showed a sharp decline in the overall market sentiment, while the index remained in the "Greed" zone on Wednesday. Via Benzinga Topics Economy Stocks Exposures Interest Rates US Equities Earnings Outlook For Quest Diagnostics January 31, 2024 Via Benzinga Earnings Scheduled For February 1, 2024 February 01, 2024 Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on... Via Benzinga Quest Diagnostics Likely To Report Higher Q4 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts February 01, 2024 Quest Diagnostics Incorporated (NYSE: DGX) is expected to release earnings results for its fourth quarter, before the opening bell on Feb. 1, 2024. Via Benzinga The Top 3 Stocks in the High-Potential ‘Cancer Testing’ Market January 18, 2024 With the value of the cancer testing market expected to soar over the next decade, here are the three best disease testing stocks to buy now. Via InvestorPlace Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns January 12, 2024 A less invasive alternative to PET scans, these tests offer quick identification for emerging treatments. Learn more about the latest advancements in Alzheimer's detection. Via Benzinga Quest Diagnostics and Ultima Collaborate to Scale Ultima’s Technology in Fast-Growing Minimal Residual Disease and Whole Genome Sequencing January 09, 2024 From Ultima Genomics Via Business Wire Consulting Firm McKinsey Concludes Opioid Litigation Settlement With $78M Agreement January 02, 2024 Consulting giant McKinsey & Co, on Friday, agreed to a settlement of $78 million to resolve allegations tied to the opioid epidemic, as disclosed in federal court papers filed in San Francisco. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
